HRP20141006T1 - Farmaceutski pripravci koji sadrže 2-okso-1-pirolidin derivate - Google Patents
Farmaceutski pripravci koji sadrže 2-okso-1-pirolidin derivate Download PDFInfo
- Publication number
- HRP20141006T1 HRP20141006T1 HRP20141006AT HRP20141006T HRP20141006T1 HR P20141006 T1 HRP20141006 T1 HR P20141006T1 HR P20141006A T HRP20141006A T HR P20141006AT HR P20141006 T HRP20141006 T HR P20141006T HR P20141006 T1 HRP20141006 T1 HR P20141006T1
- Authority
- HR
- Croatia
- Prior art keywords
- particles
- cyclodextrin
- preparation according
- mass
- relation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims 19
- 238000002360 preparation method Methods 0.000 claims 14
- 229920000858 Cyclodextrin Polymers 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- -1 2,2-difluorovinyl Chemical group 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 229960002161 brivaracetam Drugs 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Oralni farmaceutski pripravak, u čvrstom obliku tableta, koji sadrži čestice, a spomenute čestice sadrže aktivni sastojak i, kao ekscipijent, 0.1% do 60% po masi najmanje jednog ciklodekstrin agensa, u odnosu na ukupnu masu čestica; pri čemu je aktivni sastojak 2-okso-1-pirolidin derivat formule (I)
[image]
gdje,
R1 je C1-10 alkil ili C2-6 alkenil,
R2 je C1-10 alkil ili C2-6 alkenil;
X je -CONR4R5, COOH, -COOR3 ili CN;
R3 je C1-10 alkil;
R4 je vodik ili C1-10 alkil;
R5 je vodik ili C1-10 alkil.
2. Pripravak prema zahtjevu 1, naznačen time da R1 je n-propil ili 2,2-difluorovinil; R2 je etil; i X je -CONH2.
3. Pripravak prema zahtjevu 1 ili 2, naznačen time da je ciklodekstrin agens izabran između alfa ciklodekstrina, beta ciklodekstrina, hidroksipropil beta ciklodekstrina, metil beta ciklodekstrina sulfobutil beta ciklodekstrina, gama ciklodekstrina, i hidroksipropil gama ciklodekstrina.
4. Pripravak prema zahtjevu 3, naznačen time da je ciklodekstrin agens beta ciklodekstrin.
5. Pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time da čestice sadrže 1.0 do 30% po masi ciklodekstrin agensa u odnosu na ukupnu masu čestica.
6. Pripravak prema bilo kojem od prethodnih zahtjeva 1 do 5, naznačen time da čestice sadrže dezintegrant, kao ekscipijent.
7. Pripravak prema zahtjevu 6, naznačen time da je dezintegrant natrij kroskarmeloza.
8. Pripravak prema zahtjevu 6 ili 7, naznačen time da čestice sadrže 0,5 do 25% po masi dezintegranta, u odnosu na ukupnu masu čestica.
9. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da čestice sadrže diluent, kao ekscipijent.
10. Pripravak prema zahtjevu 9, naznačen time da je diluent laktoza monohidrat.
11. Pripravak prema zahtjevu 9 ili 10, naznačen time da čestice sadrže 5 do 95% po masi diluenta u odnosu na ukupnu masu čestica.
12. Pripravak prema zahtjevu 2, koji sadrži čestice, a spomenute čestice sadrže
- Brivaracetam kao aktivni sastojak;
- do 60% po masi bar jednog ciklodekstrin agensa;
- 0.5 do 25% po masi dezintegranta; i
- 5 do 95% po masi diluenta; u odnosu na ukupnu masu čestica.
13. Pripravak prema zahtjevu 2, koji se sastoji od čestica, a spomenute čestice sadrže
- Brivaracetam kao aktivni sastojak;
- do 60% po masi bar jednog ciklodekstrin agensa;
- 0.5 do 25% po masi natrij kroskarmeloze; i
- 5 do 95 po masi% laktoze monohidrata; u odnosu na ukupnu masu čestica.
14. Postupak za pripremu pripravaka prema bilo kojem od prethodnih zahtjeva, naznačen time što uključuje najmanje jedan korak suhe granulacije.
15. Postupak prema zahtjevu 14, koji uključuje
- prvi korak u kojem se aktivni sastojak, ciklodekstrin agens, i ekscipijenti miješaju;
- drugi korak u kojem se tako nastala mješavina komprimira i/ili kompaktira; i
- treći korak u kojem se mješavina melje da se dobiju čestice.
16. Postupak prema zahtjevu 15 koji uključuje
- četvrti korak u kojem se dobijene čestice, i ekscipijenti miješaju; i
- peti korak u kojem se konačna mješavina komprimira i/ili kompaktira u cilju dobivanja tableta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09100083 | 2009-01-29 | ||
| PCT/EP2010/050892 WO2010094535A1 (en) | 2009-01-29 | 2010-01-27 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141006T1 true HRP20141006T1 (hr) | 2014-12-19 |
Family
ID=40622206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141006AT HRP20141006T1 (hr) | 2009-01-29 | 2014-10-21 | Farmaceutski pripravci koji sadrže 2-okso-1-pirolidin derivate |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20120108464A1 (hr) |
| EP (1) | EP2391349B1 (hr) |
| JP (1) | JP5576401B2 (hr) |
| KR (1) | KR101640164B1 (hr) |
| CN (2) | CN104083328B (hr) |
| AU (1) | AU2010215646B2 (hr) |
| BR (1) | BRPI1007161B1 (hr) |
| CA (1) | CA2747395C (hr) |
| CY (1) | CY1115673T1 (hr) |
| DK (1) | DK2391349T3 (hr) |
| EA (1) | EA022057B1 (hr) |
| ES (1) | ES2511047T3 (hr) |
| HK (2) | HK1161988A1 (hr) |
| HR (1) | HRP20141006T1 (hr) |
| IL (1) | IL213545A (hr) |
| ME (1) | ME01927B (hr) |
| MX (1) | MX2011007267A (hr) |
| PL (1) | PL2391349T3 (hr) |
| PT (1) | PT2391349E (hr) |
| RS (1) | RS53554B1 (hr) |
| SI (1) | SI2391349T1 (hr) |
| SM (1) | SMT201400155B (hr) |
| WO (1) | WO2010094535A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2520990T3 (es) * | 2009-01-29 | 2014-11-12 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
| CN104800176A (zh) * | 2015-04-23 | 2015-07-29 | 广东赛烽医药科技有限公司 | 一种布瓦西坦口崩片及其制备方法 |
| BR112018012870A2 (pt) | 2015-12-30 | 2018-12-04 | Adamas Pharmaceuticals Inc | métodos e composições para o tratamento de transtornos relacionados à crise |
| WO2017195144A1 (en) * | 2016-05-12 | 2017-11-16 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| WO2019203870A1 (en) | 2018-04-19 | 2019-10-24 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| WO2019036713A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS |
| CN109833300A (zh) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | 一种抗癫痫药物口服组合物及其制备方法 |
| CN110638743B (zh) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
| CN113288872A (zh) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | 一种2-吡咯烷酮衍生物的组合物及其制备方法 |
| CN112933059A (zh) * | 2021-03-25 | 2021-06-11 | 浙江昂利康制药股份有限公司 | 一种布立西坦片剂的干法制粒工艺 |
| CN115192572B (zh) * | 2021-04-08 | 2023-09-19 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
| CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| PL366453A1 (en) * | 2001-05-01 | 2005-02-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
| JP2005298338A (ja) | 2002-02-27 | 2005-10-27 | Eisai Co Ltd | 速崩壊性圧縮成形製剤 |
| CN1186094C (zh) * | 2002-07-01 | 2005-01-26 | 蔡海德 | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 |
| US7799538B2 (en) * | 2005-03-09 | 2010-09-21 | Trustees Of Dartmouth College | Method for identifying agents which modulate GTPase activity involved in insulin-stimulated GLUT4 translocation |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| EA014961B1 (ru) * | 2005-07-26 | 2011-04-29 | Юсб Фарма С.А. | Фармацевтические композиции, включающие леветирацетам, и способы их получения |
| US8211936B2 (en) * | 2006-06-08 | 2012-07-03 | Ucb Pharma, S.A. | Co-crystals of pyrrolidinones |
| CA2661683C (en) | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| TW200836747A (en) * | 2007-01-05 | 2008-09-16 | Combinatorx Inc | Methods, compositions, and kits for the treatment of pain |
| ES2520990T3 (es) * | 2009-01-29 | 2014-11-12 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
-
2010
- 2010-01-27 CN CN201410370728.3A patent/CN104083328B/zh active Active
- 2010-01-27 ME MEP-2014-124A patent/ME01927B/me unknown
- 2010-01-27 EP EP10701245.2A patent/EP2391349B1/en active Active
- 2010-01-27 SI SI201030776T patent/SI2391349T1/sl unknown
- 2010-01-27 RS RSP20140539 patent/RS53554B1/en unknown
- 2010-01-27 AU AU2010215646A patent/AU2010215646B2/en active Active
- 2010-01-27 DK DK10701245.2T patent/DK2391349T3/da active
- 2010-01-27 US US13/142,869 patent/US20120108464A1/en not_active Abandoned
- 2010-01-27 US US13/146,074 patent/US10729653B2/en active Active
- 2010-01-27 ES ES10701245.2T patent/ES2511047T3/es active Active
- 2010-01-27 KR KR1020117019926A patent/KR101640164B1/ko active IP Right Grant
- 2010-01-27 BR BRPI1007161-0A patent/BRPI1007161B1/pt active IP Right Grant
- 2010-01-27 CN CN201080005399.2A patent/CN102292071B/zh active Active
- 2010-01-27 PT PT107012452T patent/PT2391349E/pt unknown
- 2010-01-27 WO PCT/EP2010/050892 patent/WO2010094535A1/en active Application Filing
- 2010-01-27 CA CA2747395A patent/CA2747395C/en active Active
- 2010-01-27 PL PL10701245T patent/PL2391349T3/pl unknown
- 2010-01-27 JP JP2011546825A patent/JP5576401B2/ja active Active
- 2010-01-27 EA EA201101116A patent/EA022057B1/ru unknown
- 2010-01-27 MX MX2011007267A patent/MX2011007267A/es active IP Right Grant
-
2011
- 2011-06-14 IL IL213545A patent/IL213545A/en active IP Right Grant
-
2012
- 2012-03-14 HK HK12102566.6A patent/HK1161988A1/zh unknown
-
2014
- 2014-10-21 HR HRP20141006AT patent/HRP20141006T1/hr unknown
- 2014-10-23 CY CY20141100876T patent/CY1115673T1/el unknown
- 2014-10-23 SM SM201400155T patent/SMT201400155B/xx unknown
- 2014-11-21 HK HK14111804.7A patent/HK1198287A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141006T1 (hr) | Farmaceutski pripravci koji sadrže 2-okso-1-pirolidin derivate | |
| HRP20170325T1 (hr) | Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu | |
| HRP20181740T4 (hr) | Farmaceutski pripravci za liječenje bolesti koje su posredovane s cftr | |
| MEP46008A (hr) | Čvrste farmaceutske formulacije koje sadrže telmisartan | |
| MX355183B (es) | Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico. | |
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| MX2011005633A (es) | Formas de dosificacion solida de bendamustina. | |
| MX364937B (es) | Composiciones farmaceuticas de acido 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico y su administracion. | |
| NO20092314L (no) | Benzamidderivater som EP4 receptoragonister | |
| HRP20230691T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
| TNSN07274A1 (en) | Direct compression formulation and process | |
| HRP20030726B1 (hr) | Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| MY151240A (en) | Solid pharmaceutical formulations comprising bibw 2992 | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| WO2008065097A3 (en) | Stabilized solid pharmaceutical composition of candesartan cilexetil | |
| SI2271348T1 (en) | PERORAL TABLETS WITH TETRACYCLINE COMPOUNDS | |
| UA95274C2 (ru) | Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления | |
| HRP20211795T1 (hr) | Antifungalna farmaceutska formulacija | |
| NZ596275A (en) | Burst drug release compositions | |
| CN105579065A (zh) | 包含呈共晶体形式的阿戈美拉汀的阿戈美拉汀制剂 | |
| JPWO2017142001A1 (ja) | 口腔内速崩壊性錠剤用造粒物 | |
| WO2011080570A8 (en) | Extended release pharmaceutical composition comprising linezolid and process for preparing the same | |
| NZ614975A (en) | Ectoparasiticidal methods and formulations |